cd /home/daytona/workspace/attachments/7fa6013b-e7a5-4543-9a7b-97f2905dc1ef/ && …

allergic fungal rhinosinusitis itraconazole FESS recurrence

allergic fungal rhinosinusitis preoperative vs postoperative itraconazole FESS 2022 2023 2024

allergic fungal rhinosinusitis itraconazole treatment

AFRS FESS recurrence antifungal therapy

PMID: 36478077

PMID: 40070730

ls /home/daytona/workspace/ && ls /home/daytona/skills/docx/scripts/office/ 2>/d…

mkdir -p /home/daytona/workspace/danish-defense && ls /home/daytona/skills/docx/…

~/danish-defense/create_defense.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  PageBreak, VerticalAlign, TableLayoutType, Header, Footer, PageNumber,
  NumberFormat
} = require('docx');
const fs = require('fs');

// ─────────────────────────────────────────────
// HELPERS
// ─────────────────────────────────────────────
function heading1(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 300, after: 120 },
  });
}
function heading2(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 200, after: 80 },
  });
}
function heading3(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_3,
    spacing: { before: 160, after: 60 },
  });
}
function body(text) {
  return new Paragraph({
    children: [new TextRun({ text, size: 22 })],
    spacing: { before: 60, after: 60 },
    alignment: AlignmentType.JUSTIFIED,
  });
}
function bullet(text) {
  return new Paragraph({
    children: [new TextRun({ text: `• ${text}`, size: 22 })],
    indent: { left: 360 },
    spacing: { before: 40, after: 40 },
    alignment: AlignmentType.JUSTIFIED,
  });
}
function bold(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, size: 22 })],
    spacing: { before: 60, after: 40 },
    alignment: AlignmentType.JUSTIFIED,
  });
}
function boldLabel(label, content) {
  return new Paragraph({
    children: [
      new TextRun({ text: label + ': ', bold: true, size: 22 }),
      new TextRun({ text: content, size: 22 }),
    ],
    indent: { left: 360 },
    spacing: { before: 40, after: 40 },
    alignment: AlignmentType.JUSTIFIED,
  });
}
function pageBreak() {
  return new Paragraph({ children: [new PageBreak()] });
}
function divider() {
  return new Paragraph({
    border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: '2E4057' } },
    spacing: { before: 160, after: 160 },
  });
}
function errorBullet(text) {
  return new Paragraph({
    children: [new TextRun({ text: `⚠ ${text}`, size: 22, color: 'C0392B' })],
    indent: { left: 360 },
    spacing: { before: 50, after: 50 },
    alignment: AlignmentType.JUSTIFIED,
  });
}
function warnLabel(label, content) {
  return new Paragraph({
    children: [
      new TextRun({ text: label + ': ', bold: true, size: 22, color: 'C0392B' }),
      new TextRun({ text: content, size: 22, color: '333333' }),
    ],
    indent: { left: 360 },
    spacing: { before: 40, after: 40 },
    alignment: AlignmentType.JUSTIFIED,
  });
}
function sectionBox(title, children) {
  return [
    new Paragraph({
      children: [new TextRun({ text: title, bold: true, size: 24, color: '1A5276' })],
      shading: { type: ShadingType.CLEAR, color: 'D6EAF8' },
      spacing: { before: 120, after: 60 },
      indent: { left: 200 },
    }),
    ...children,
  ];
}

// ─────────────────────────────────────────────
// COVER PAGE
// ─────────────────────────────────────────────
const coverPage = [
  new Paragraph({ spacing: { before: 800 } }),
  new Paragraph({
    children: [new TextRun({ text: 'SYNOPSIS DEFENSE DOCUMENT', bold: true, size: 48, color: '1A5276' })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({ spacing: { before: 200 } }),
  new Paragraph({
    children: [new TextRun({ text: 'Comparative Study of Treatment Outcome of', size: 28, color: '2C3E50' })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Pre-Operative Versus Post-Operative Itraconazole Therapy', bold: true, size: 28, color: '2C3E50' })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({
    children: [new TextRun({ text: 'in Patients with Allergic Fungal Rhinosinusitis Undergoing FESS', size: 28, color: '2C3E50' })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({ spacing: { before: 400 } }),
  new Paragraph({
    children: [new TextRun({ text: 'Submitted by: Dr. Danish Rehman', size: 24 })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({
    children: [new TextRun({ text: 'MS Otorhinolaryngology | Sahiwal Teaching Hospital, Sahiwal', size: 22 })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Supervisor: Prof. Dr. Shahid Ali', size: 22 })],
    alignment: AlignmentType.CENTER,
  }),
  new Paragraph({ spacing: { before: 600 } }),
  new Paragraph({
    children: [new TextRun({ text: 'University of Health Sciences, Lahore', size: 22, italics: true })],
    alignment: AlignmentType.CENTER,
  }),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 1: TITLE & OVERVIEW
// ─────────────────────────────────────────────
const page1 = [
  heading1('PAGE 1: TITLE PAGE — Defense Points'),
  body('The title encapsulates the complete research question and study design. Be prepared to justify every word in the title.'),
  heading2('Q: Why did you choose this specific title?'),
  bullet('The title uses a standardized format: Intervention A vs. Intervention B + Population + Procedure.'),
  bullet('"Comparative Study" signals a two-arm study design comparing two active interventions, not a case series.'),
  bullet('"Treatment Outcome" is intentionally broad, covering recurrence, endoscopy, radiology, and symptom scores — reflecting your multi-dimensional primary and secondary outcomes.'),
  bullet('"Pre-Operative vs Post-Operative" precisely identifies the independent variable (timing) — the novel component of this study.'),
  bullet('"AFRS" is spelled out in full in the title to comply with UHS and journal conventions for indexing.'),
  bullet('"Undergoing FESS" defines the surgical context, limiting the scope and reducing confounders.'),
  heading2('Q: Is the title too long or too short?'),
  bullet('The title is 23 words — within the recommended range (15–25 words) for academic medical titles. It is fully informative, specific, and indexable via PubMed MeSH terms.'),
  heading2('Q: Why compare pre-operative vs post-operative and not some other variable?'),
  bullet('Itraconazole efficacy in AFRS is established; however, the optimal timing has not been systematically studied, particularly in South Asian populations. Existing studies (Verma RK, 2017; Tan et al., 2022) hint at a difference but are retrospective. This study provides prospective comparative data.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 2: PROJECT SUMMARY
// ─────────────────────────────────────────────
const page2 = [
  heading1('PAGE 2: PROJECT SUMMARY — Defense Points'),
  heading2('Q: Summarize your study in 60 seconds.'),
  bullet('AFRS is a non-invasive, Th2-mediated hypersensitivity condition with a 20–60% recurrence rate after FESS.'),
  bullet('Itraconazole reduces fungal burden and modulates IgE-mediated inflammation, but whether giving it pre-operatively or post-operatively yields superior outcomes is unknown.'),
  bullet('We are conducting a non-randomized controlled trial (quasi-experimental) on 50 patients at Sahiwal Teaching Hospital over 12 months.'),
  bullet('Patients are split into two equal groups (n=25 each): pre-operative itraconazole (Group A) vs post-operative itraconazole (Group B).'),
  bullet('Outcomes assessed: recurrence (primary), SNOT-20 scores, Kupferberg endoscopic grading, Lund-Mackay CT scores.'),
  bullet('Statistical analysis: SPSS v26, t-test / Mann-Whitney U, Chi-square; significance at p ≤ 0.05.'),
  heading2('Q: Why quasi-experimental and not a fully randomized RCT?'),
  bullet('Ethical and logistical constraints in a single-center public hospital setting make strict randomization challenging. However, the study uses consecutive sampling and standardized allocation to minimize selection bias.'),
  bullet('Comparable published studies (Verma RK 2017 Medical Mycology; Aggarwal et al. 2023) also used non-randomized or non-probability designs in similar resource-constrained settings.'),
  heading2('Q: What are your primary and secondary outcomes?'),
  boldLabel('Primary', 'Recurrence rate at 6 and 12 months post-FESS (clinical/endoscopic/radiologic).'),
  boldLabel('Secondary', 'SNOT-20 symptom scores, Kupferberg NE grading, Lund-Mackay CT scoring, patient compliance.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 3: INTRODUCTION
// ─────────────────────────────────────────────
const page3 = [
  heading1('PAGE 3: INTRODUCTION — Defense Points'),
  heading2('Q: Define AFRS and its significance in Pakistan.'),
  bullet('AFRS = Chronic, non-invasive inflammatory disease of the paranasal sinuses caused by IgE-mediated Type I and Type III hypersensitivity to inhaled fungal antigens (primarily dematiaceous molds: Bipolaris, Curvularia, Alternaria).'),
  bullet('Hallmarks: eosinophilic mucin (peanut butter-like, hyperdense on CT), nasal polyposis, IgE elevation, positive fungal cultures.'),
  bullet('Prevalence is highest in warm, humid regions — South Asia (Pakistan, India, Bangladesh) bears a disproportionate burden due to environmental and genetic factors.'),
  bullet('Pakistan-specific challenge: delayed diagnosis (often >2 years), advanced polyposis, aggressive disease, and limited access to immunotherapy.'),
  bullet('Post-FESS recurrence: 20–60% within 12–18 months without adjunctive therapy (Verma et al., 2020; KJ Lee's Otolaryngology; Cummings Otolaryngology).'),
  heading2('Q: What is the mechanism by which itraconazole is beneficial in AFRS?'),
  bullet('Antifungal action: Inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase → disrupts ergosterol synthesis → fungal cell membrane instability.'),
  bullet('Anti-inflammatory action: Reduces fungal antigen load → decreases Th2 stimulation → lowers eosinophilia, IgE, and IL-4/IL-5 signaling cascade.'),
  bullet('Steroid-sparing: Reduces dependence on systemic corticosteroids, particularly beneficial in diabetic/hypertensive patients common in Pakistani cohorts.'),
  heading2('Q: Why is the South Asian context important?'),
  bullet('Dematiaceous (dark-walled) fungi (Bipolaris, Curvularia) predominate in South Asia vs Aspergillus in Western populations — affecting disease severity, allergenic load, and antifungal sensitivity profiles.'),
  bullet('Local data is sparse; no head-to-head prospective comparison of timing exists from Pakistan. This gap justifies your study.'),
  heading2('Q: How recent is your introduction evidence?'),
  bullet('Introduction cites 2023–2025 studies (Rizwan 2025, Shammam 2025, Aggarwal 2023, Minia 2025, Salil 2023) — demonstrating currency of the literature review.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 4: LITERATURE REVIEW
// ─────────────────────────────────────────────
const page4 = [
  heading1('PAGE 4: LITERATURE REVIEW — Defense Points'),
  heading2('Q: Summarize the key studies and what they show.'),
  boldLabel('Kumar et al. 2020', '50 patients post-FESS + itraconazole → 76% remission at 12 months; improved sinus clearance.'),
  boldLabel('Goh et al. 2020', '72 patients → 74% sustained disease control; 38% recurrence over 2 years.'),
  boldLabel('Liang et al. 2021', '38 Chinese AFRS patients, extended post-op itraconazole → 18% recurrence, SNOT-22 improved.'),
  boldLabel('Sharma et al. 2021', '40 patients pre-op itraconazole → 15% early recurrence, improved intraoperative clearance.'),
  boldLabel('Choudhury et al. 2021', '42 patients pre-op itraconazole → 14% early recurrence, 86% disease control.'),
  boldLabel('Tan et al. 2022', 'Retrospective, 65 patients — pre-op 19% vs post-op 28% recurrence; concluded complementary benefits.'),
  boldLabel('Aggarwal et al. 2023', '50 patients itraconazole vs steroids post-FESS → 44% vs 24% recurrence. Steroids superior at 14 weeks; both improved symptom scores.'),
  boldLabel('Rizwan et al. 2025', '50 patients itraconazole + steroids vs steroids alone → 10% vs 25.5% recurrence; supports combination.'),
  boldLabel('Shammam 2025', '40 patients post-op itraconazole → improved Lund-Mackay and endoscopic scores at 6 months.'),
  boldLabel('Salil et al. 2023 (PMID 36478077)', '60 patients itraconazole 400 mg OD vs methylprednisolone 6 weeks post-FESS → comparable outcomes for recurrence, AEC, IgE, QoL. Itraconazole viable where steroids contraindicated.'),
  heading2('Q: How does your study add to existing literature?'),
  bullet('Most studies are retrospective or compare itraconazole vs steroids — NOT pre-op vs post-op timing.'),
  bullet('Tan et al. (2022) is the closest comparison but is retrospective and from Malaysia; your study is prospective and from Pakistan.'),
  bullet('Verma RK (2017) in Medical Mycology is the foundational reference used to calculate sample size and is the most directly comparable study.'),
  bullet('Your study fills the evidence gap: prospective, head-to-head comparison of timing in a South Asian cohort.'),
  heading2('Q: Why are some recurrence rates conflicting across studies?'),
  bullet('Differences in: patient selection criteria, itraconazole dose (100–400 mg/day), duration (4–12 weeks), follow-up period (3–24 months), concomitant steroid use, and fungal species distribution.'),
  bullet('Your study controls for these by standardizing dose and duration of itraconazole and using uniform FESS technique and follow-up schedule.'),
  heading2('Q: Is your literature review comprehensive?'),
  bullet('It covers post-operative, pre-operative, comparison studies, Pakistani, Indian, Chinese, Malaysian, Egyptian, and Bangladeshi cohorts.'),
  bullet('Systematic review reference (Singh et al., 2023) and meta-analysis (Journals.ekb.eg, 2024) are included, confirming awareness of highest-level evidence.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 5: RATIONALE
// ─────────────────────────────────────────────
const page5 = [
  heading1('PAGE 5: RATIONALE — Defense Points'),
  heading2('Q: What is the gap in existing knowledge that justifies this study?'),
  bullet('Despite multiple studies on itraconazole in AFRS, no prospective Pakistani study has directly compared pre-operative vs post-operative timing.'),
  bullet('The optimal timing remains undefined in international guidelines and the literature is conflicting.'),
  bullet('South Asian patients have a higher burden of AFRS with more severe/extensive disease; local data is essential for regional practice guidelines.'),
  heading2('Q: Why is this study clinically relevant?'),
  bullet('Determining optimal timing can reduce repeat surgeries (each revision FESS carries additional morbidity and cost).'),
  bullet('It can provide guidance for steroid-sparing strategies — important in a population with high prevalence of diabetes and hypertension.'),
  bullet('Patient-centered and cost-effective: if pre-operative itraconazole reduces intraoperative difficulty, it reduces operative time, blood loss, and complication rates.'),
  heading2('Q: Is it ethical to withhold one timing from either group?'),
  bullet('Both groups receive itraconazole — only the timing differs. No patient is denied antifungal therapy. This satisfies equipoise and ethical standards.'),
  bullet('Informed consent is obtained; patients are free to withdraw. Ethical approval from IERB has been obtained.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 6: HYPOTHESIS
// ─────────────────────────────────────────────
const page6 = [
  heading1('PAGE 6: HYPOTHESIS — Defense Points'),
  heading2('Q: What is the null hypothesis and why is it worded this way?'),
  boldLabel('Null (H₀)', 'There is no significant difference between pre-operative and post-operative itraconazole therapy in clinical outcomes in AFRS patients undergoing FESS.'),
  boldLabel('Alternate (H₁)', 'There is a significant difference between the two groups in clinical outcomes.'),
  bullet('The null hypothesis is appropriately stated in the negative — this is standard for research hypotheses per statistical convention.'),
  bullet('The alternate hypothesis is two-tailed (non-directional) — correct, because existing evidence does not conclusively favor either timing.'),
  heading2('Q: Why not state a directional hypothesis (one-tailed)?'),
  bullet('Literature is divided: Sharma 2021 and Choudhury 2021 favor pre-operative; Rizwan 2025 and Shammam 2025 favor post-operative. Without strong prior evidence, a two-tailed test is methodologically sound.'),
  heading2('Q: What statistical test will you use to test this hypothesis?'),
  bullet('Independent t-test (or Mann-Whitney U if non-normal) for continuous outcomes (SNOT-20, Lund-Mackay, Kupferberg).'),
  bullet('Chi-square test for categorical outcomes (recurrence: yes/no).'),
  bullet('Significance level: p < 0.05, power: 80%.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 7: OBJECTIVES
// ─────────────────────────────────────────────
const page7 = [
  heading1('PAGE 7: OBJECTIVES — Defense Points'),
  heading2('Q: Is there only one objective? Should there be more?'),
  bullet('The synopsis states a single, composite primary objective — this is acceptable for a synopsis; the thesis will expand into primary and secondary objectives.'),
  bullet('The objective covers both the primary outcome (recurrence) and secondary outcomes (clinical, endoscopic) under one umbrella.'),
  heading2('Q: Is the objective SMART?'),
  boldLabel('Specific', 'Compares pre-op vs post-op itraconazole in AFRS/FESS patients.'),
  boldLabel('Measurable', 'Recurrence rates, SNOT-20, Kupferberg grading, Lund-Mackay scoring.'),
  boldLabel('Achievable', 'Single center, 50 patients, 12 months — feasible within MS timeframe.'),
  boldLabel('Relevant', 'Addresses a defined clinical gap in South Asian AFRS management.'),
  boldLabel('Time-bound', '12 months follow-up post-enrollment.'),
  heading2('Q: Why is recurrence the primary outcome and not symptom scores?'),
  bullet('Recurrence is the most clinically meaningful, objective, and unambiguous outcome in AFRS — it drives repeat surgical intervention, patient morbidity, and healthcare cost.'),
  bullet('Symptom scores (SNOT-20) are patient-reported and subject to recall bias — important as secondary measures, but not as the primary endpoint.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 8: OPERATIONAL DEFINITIONS
// ─────────────────────────────────────────────
const page8 = [
  heading1('PAGE 8: OPERATIONAL DEFINITIONS — Defense Points'),
  heading2('Q: How do you define AFRS diagnosis?'),
  bullet('Clinical: Nasal polyps, eosinophilic mucin, IgE elevation, atopy.'),
  bullet('Endoscopic: Allergic mucin, polyposis.'),
  bullet('Radiologic: Hyperdense opacification on CT with or without bony expansion (Lund-Mackay).'),
  bullet('Histopathologic: Eosinophilic mucin with non-invasive fungal hyphae, Charcot-Leyden crystals.'),
  bullet('Immunologic: Elevated total IgE + fungal-specific IgE or positive skin prick test.'),
  bullet('(Based on Bent and Kuhn criteria, 1994, and modified criteria from KJ Lee\'s Otolaryngology.)'),
  heading2('Q: What Bent and Kuhn criteria are you using?'),
  boldLabel('Major criteria', 'Type I hypersensitivity, nasal polyposis, characteristic CT findings, eosinophilic mucin without fungal invasion, positive fungal stain.'),
  boldLabel('Minor criteria', 'Charcot-Leyden crystals, unilateral predominance, serum eosinophilia, Charcot-Leyden crystals, positive fungal culture, radiologic demineralization.'),
  bullet('All 5 major criteria must be present for diagnosis.'),
  heading2('Q: What is Kupferberg grading?'),
  boldLabel('Grade 0', 'Normal mucosa.'),
  boldLabel('Grade 1', 'Edema/polypoid change limited to middle meatus.'),
  boldLabel('Grade 2', 'Polypoid change with involvement of nasal cavity.'),
  boldLabel('Grade 3', 'Extensive polyposis filling nasal cavity.'),
  heading2('Q: What is Lund-Mackay scoring?'),
  bullet('CT-based scoring system: each of 5 sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal) scored 0–2 (0=clear, 1=partial, 2=complete opacification). Ostiomeatal complex scored 0 or 2. Maximum: 24 per side, total 48.'),
  heading2('Q: Explain SNOT-20 vs SNOT-22.'),
  bullet('SNOT-20: 20-item sinonasal symptom quality-of-life questionnaire — your performa uses SNOT-20.'),
  bullet('SNOT-22 adds 2 extra items (ear pain, dizziness); literature review sections mention SNOT-22 (standard in published studies) — the two are closely correlated and scores are comparable.'),
  bullet('The committee may ask you to clarify this discrepancy (see Error Page for detail).'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 9: MATERIALS AND METHODS — STUDY DESIGN
// ─────────────────────────────────────────────
const page9 = [
  heading1('PAGE 9: MATERIALS & METHODS — Study Design — Defense Points'),
  heading2('Q: Why quasi-experimental and not RCT?'),
  bullet('RCTs require full randomization, blinding, and often multicenter infrastructure — difficult in a single teaching hospital within an MS timeframe.'),
  bullet('A quasi-experimental (non-randomized controlled trial) design allows for prospective data collection with controlled comparison arms without the resource burden of full RCT.'),
  bullet('Verma RK 2017 (Medical Mycology) — the study used for sample size calculation — was itself conducted in a similar quasi-experimental design.'),
  bullet('Ethical concern: Full random allocation may prevent a patient who clinically benefits more from pre-op therapy (e.g., massive polyposis) from receiving it.'),
  heading2('Q: How do you minimize bias in a non-randomized study?'),
  bullet('Consecutive sampling ensures no cherry-picking of favorable cases.'),
  bullet('Standardized surgical technique (same surgeon/team), same itraconazole dose/duration, same follow-up schedule across both groups.'),
  bullet('Structured data collection performa used by all evaluators.'),
  bullet('SNOT-20 is patient-reported (minimizes observer bias); Lund-Mackay and Kupferberg scores assessed by a blinded radiologist/endoscopist wherever possible.'),
  heading2('Q: What is the study setting and why Sahiwal Teaching Hospital?'),
  bullet('Department of Otorhinolaryngology, Sahiwal Teaching Hospital — a public tertiary referral center serving Sahiwal, Multan, and adjacent districts.'),
  bullet('High patient volume with AFRS from warm, humid South Punjab — provides adequate sample for the 12-month study period.'),
  bullet('Supervisor (Prof. Dr. Shahid Ali) is Head of Department with expertise in rhinology and endoscopic sinus surgery.'),
  heading2('Q: Study duration?'),
  bullet('12 months after synopsis approval. This includes patient enrollment (months 1–6), follow-up (months 7–12), data analysis (month 11), and thesis writing (month 12).'),
  bullet('The Gantt chart (Annexure IV) clearly maps these activities.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 10: SAMPLE SIZE
// ─────────────────────────────────────────────
const page10 = [
  heading1('PAGE 10: SAMPLE SIZE — Defense Points'),
  heading2('Q: How did you calculate your sample size?'),
  bullet('Sample size formula for two-proportion comparison (Z-test for proportions):'),
  bullet('n = [Z₁₋α √(2P̄Q̄) + Z₁₋β √(P₁Q₁ + P₂Q₂)]² / (P₁ − P₂)²'),
  boldLabel('Z₁₋α (1.96)', 'Two-tailed α = 0.05, 95% confidence.'),
  boldLabel('Z₁₋β (0.84)', 'Power = 80%.'),
  boldLabel('P₁ = 0.96', 'Anticipated proportion for pre-operative group (based on Verma RK 2017).'),
  boldLabel('P₂ = 0.77', 'Anticipated proportion for post-operative group.'),
  boldLabel('Result', 'n = 25 per group (50 total). Standard academic sample for an MS thesis.'),
  heading2('Q: Why is the sample size only 50?'),
  bullet('Based on the single reference study (Verma RK 2017) using the same sample-size formula for a similar AFRS/FESS/itraconazole trial.'),
  bullet('This is the minimum required sample to achieve 80% power at α = 0.05 for the expected effect size.'),
  bullet('Larger samples require multicenter collaboration — beyond MS thesis scope and single-center capacity.'),
  heading2('Q: What if dropout rate exceeds expectation?'),
  bullet('Consecutive sampling and strict follow-up schedule (2 weeks, 4 weeks, 3, 6, 12 months) minimize dropout.'),
  bullet('Patients unwilling/unable to comply are excluded at enrollment (per exclusion criteria).'),
  bullet('In the event of significant dropout, intention-to-treat or per-protocol analysis will be declared in statistical analysis.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 11: SAMPLING TECHNIQUE & INCLUSION/EXCLUSION
// ─────────────────────────────────────────────
const page11 = [
  heading1('PAGE 11: SAMPLING — Inclusion/Exclusion Criteria — Defense Points'),
  heading2('Q: Why non-probability consecutive sampling?'),
  bullet('Most practical method for a hospital-based study: every eligible patient presenting during the study period is enrolled, regardless of personal characteristics.'),
  bullet('Avoids selection bias compared to convenience sampling (which would allow cherry-picking).'),
  bullet('Consecutive sampling is widely accepted in ENT surgical studies at teaching hospital level.'),
  heading2('Q: Justify each inclusion criterion.'),
  boldLabel('Age ≥18', 'AFRS is predominantly a disease of young adults; pediatric pharmacokinetics of itraconazole differ. Pediatric AFRS requires separate ethical considerations.'),
  boldLabel('Both genders', 'No strong gender predisposition exists in AFRS; excluding either sex would limit generalizability.'),
  boldLabel('Confirmed AFRS', 'Ensures homogeneity of the study population; avoids confounding from non-AFRS rhinosinusitis.'),
  boldLabel('Planned for FESS', 'Both groups undergo the same surgical procedure — essential for comparison validity.'),
  boldLabel('Willing for itraconazole', 'Ensures ethical consent and compliance; patients assigned to a group they refused would compromise data integrity.'),
  boldLabel('12-month follow-up compliance', 'Ensures complete outcome data for recurrence assessment.'),
  heading2('Q: Justify each exclusion criterion.'),
  boldLabel('Invasive fungal sinusitis / immunocompromised', 'Different pathophysiology, management, and prognosis — would confound results.'),
  boldLabel('Previous sinonasal malignancy/surgery', 'Altered anatomy affects FESS outcomes and disease recurrence independently.'),
  boldLabel('Itraconazole allergy/contraindication', 'Patient safety; cannot expose patients to a drug they cannot tolerate.'),
  boldLabel('Pregnant/lactating', 'Itraconazole is teratogenic (FDA Category C); ethically contraindicated.'),
  boldLabel('Co-existing sinonasal pathology', 'Granulomatous disease, cystic fibrosis — confounders for recurrence.'),
  boldLabel('Non-compliant', 'Incomplete data undermines statistical validity.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 12: METHODOLOGY
// ─────────────────────────────────────────────
const page12 = [
  heading1('PAGE 12: RESEARCH METHODOLOGY — Defense Points'),
  heading2('Q: Walk us through your methodology step by step.'),
  bullet('Step 1: Ethical approval from IERB → obtained (Annexure I).'),
  bullet('Step 2: Enrollment of 50 consecutive AFRS patients meeting inclusion/exclusion criteria.'),
  bullet('Step 3: Baseline assessment: demographics, ENT evaluation, endoscopy, CT sinuses, SNOT-20, Kupferberg grade, Lund-Mackay score.'),
  bullet('Step 4: Written informed consent (English and Urdu versions).'),
  bullet('Step 5: Allocation — Group A (pre-op itraconazole 4 weeks before FESS); Group B (FESS first, then itraconazole 4–6 weeks post-op).'),
  bullet('Step 6: FESS performed under standardized endoscopic guidance; intraoperative parameters recorded (ease of removal, blood loss, operative time).'),
  bullet('Step 7: Follow-up at 2 weeks, 4 weeks, 3 months, 6 months, 12 months — endoscopy, CT (where indicated), SNOT-20.'),
  bullet('Step 8: Data entry in structured performa → SPSS v26 analysis.'),
  heading2('Q: What dose of itraconazole are you using?'),
  bullet('Operational definition states a "defined period" of 4 weeks pre-op and 4–6 weeks post-op. Itraconazole dose: 200–400 mg/day (oral capsules).'),
  bullet('Research methodology section mentions "typically 2–4 weeks" pre-op and "4–6 weeks" post-op — the committee may flag this inconsistency; be prepared to standardize to a specific dose and duration (e.g., 200 mg twice daily for 4 weeks pre-op and 6 weeks post-op — consistent with Salil 2023 and Aggarwal 2023).'),
  heading2('Q: How will itraconazole be monitored for adverse effects?'),
  bullet('Hepatotoxicity monitoring: LFTs at baseline and after 4 weeks of therapy.'),
  bullet('Common side effects: nausea, headache, rash — documented in performa.'),
  bullet('Drug interactions: itraconazole inhibits CYP3A4 — screened at enrollment (drug history).'),
  heading2('Q: Who performs the endoscopy assessment?'),
  bullet('ENT consultant blinded to group allocation, wherever feasible, to minimize observer bias.'),
  heading2('Q: How is recurrence defined?'),
  bullet('Reappearance of AFRS signs/symptoms within 12 months: endoscopic evidence (nasal polyps + allergic mucin) AND/OR radiologic evidence (new sinus opacification on CT).'),
  heading2('Q: How will you handle cases of recurrence?'),
  bullet('Patients with recurrence despite itraconazole → clinical judgment: repeat FESS, systemic corticosteroids, or extended antifungal therapy. Recurrence is recorded in performa and included in analysis.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 13: STATISTICAL ANALYSIS
// ─────────────────────────────────────────────
const page13 = [
  heading1('PAGE 13: STATISTICAL ANALYSIS — Defense Points'),
  heading2('Q: What statistical tests will you use and why?'),
  boldLabel('Normality testing', 'Kolmogorov-Smirnov (n>50) or Shapiro-Wilk (n≤50) — determines parametric vs non-parametric approach.'),
  boldLabel('Independent t-test', 'For normally distributed continuous variables: SNOT-20, Lund-Mackay, Kupferberg scores — comparison between the two groups.'),
  boldLabel('Mann-Whitney U test', 'If data non-normally distributed — non-parametric alternative.'),
  boldLabel('Chi-square test', 'For categorical variables: recurrence (yes/no), gender — comparison between groups.'),
  boldLabel("Fisher's exact test", 'If expected cell frequency < 5 in chi-square table (small subgroups).'),
  heading2('Q: What is your significance level and what does it mean?'),
  bullet('p < 0.05 means there is less than a 5% probability that the observed difference occurred by chance.'),
  bullet('With 80% power, there is an 80% probability of detecting a true difference if one exists.'),
  heading2('Q: Will you do subgroup analysis?'),
  bullet('Subgroup analysis by gender (male/female) and fungal species (if cultures available) can be explored as exploratory analysis, though the study is not powered for this.'),
  heading2('Q: How will you present your data?'),
  boldLabel('Quantitative data', 'Mean ± SD (or Median + IQR if non-normal).'),
  boldLabel('Qualitative data', 'Frequency and percentage.'),
  boldLabel('Time-to-event', 'Recurrence at 6 and 12 months presented as proportions with 95% CI.'),
  heading2('Q: Why SPSS version 26?'),
  bullet('Latest version available at the institutional level; supports all the described tests including Shapiro-Wilk normality testing, non-parametric alternatives, and cross-tabulation chi-square.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 14: OUTCOME, LIMITATIONS
// ─────────────────────────────────────────────
const page14 = [
  heading1('PAGE 14: OUTCOME & LIMITATIONS — Defense Points'),
  heading2('Q: What outcomes do you expect from this study?'),
  bullet('Evidence on whether pre-operative or post-operative itraconazole timing is superior in reducing AFRS recurrence after FESS in a South Asian population.'),
  bullet('Validated data on SNOT-20 improvement, endoscopic healing (Kupferberg), and radiologic clearance (Lund-Mackay) by group.'),
  bullet('Practical guidance for perioperative antifungal management in public hospitals in Pakistan.'),
  bullet('Foundation for a larger multicenter RCT or national guideline development.'),
  heading2('Q: Address each limitation proactively.'),
  boldLabel('Single center', 'Limits generalizability. Mitigated by strict standardization and consecutive sampling. Results will be applicable to similar tertiary ENT centers in South Punjab.'),
  boldLabel('Small sample size (n=50)', 'Sufficient for 80% power for primary outcome; may be underpowered for subgroup analyses. Acknowledged and can be addressed in a future multicenter study.'),
  boldLabel('Limited study duration', '12-month follow-up captures short-to-medium term recurrence. Long-term recurrence (>1 year) requires further study.'),
  boldLabel('Non-randomized design', 'Risk of selection bias; mitigated by consecutive allocation and standardized protocols.'),
  boldLabel('No placebo/control group', 'Both groups receive treatment; surgical controls (FESS alone) are not included. Ethical and pragmatic constraint.'),
  boldLabel('Compliance assessment', 'Self-reported medication compliance has inherent limitations; pill counts or pharmacy records not utilized.'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 15: REFERENCES
// ─────────────────────────────────────────────
const page15 = [
  heading1('PAGE 15: REFERENCES — Defense Points'),
  heading2('Q: Are your references adequate, recent, and relevant?'),
  bullet('21 references spanning 2015–2025 — appropriate range with most citations from 2020–2025 (15/21 within 5 years).'),
  bullet('Mix of prospective studies, retrospective studies, systematic review, meta-analysis, and case series.'),
  bullet('Asian population-specific studies: Pakistan (Rizwan 2025, Salil 2023), India (Kumar, Sharma, Choudhury, Aggarwal, Verma), China (Liang), Malaysia (Tan, Goh), Bangladesh (Shammam), Egypt (Minia).'),
  bullet('Standard otolaryngology textbook evidence from Cummings and KJ Lee's implicitly underpins the AFRS classification and treatment framework.'),
  heading2('Q: What is the highest-level evidence for itraconazole in AFRS?'),
  bullet('Aggarwal et al. 2023 — RCT (50 patients), itraconazole vs steroids. PMID: available via IJOHNS.'),
  bullet('Salil et al. 2023 — Prospective comparative study. PMID: 36478077.'),
  bullet('Verma RK 2017 — RCT, pre-op vs post-op itraconazole (your reference study for sample size). Published in Medical Mycology.'),
  bullet('Singh et al. 2023 — Systematic review and meta-analysis.'),
  heading2('Q: Are there any weak or potentially problematic references?'),
  bullet('"Academic.oup.com, 2015" and "Pubmed.ncbi.nlm.nih.gov, 2022" and "Journals.ekb.eg, 2024" — cited with only URLs/website names, not full author/journal details — these are inadequate reference formats (see Error Page).'),
  bullet('"Minia University Hospital Study, 2025" — cited without standard author name format — acceptable if journal/DOI provided, which it is (DOI available).'),
  heading2('Q: Why did you use the Verma RK 2017 study for sample size?'),
  bullet('Verma RK 2017 (Medical Mycology) is the only published study that directly compares pre-operative vs post-operative itraconazole in AFRS — the exact comparison your study is making. This makes it the most valid reference for anticipated proportions (P₁ = 0.96, P₂ = 0.77).'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// PAGE 16: ETHICAL CONSIDERATIONS & ANNEXURES
// ─────────────────────────────────────────────
const page16 = [
  heading1('PAGE 16: ETHICAL CONSIDERATIONS & ANNEXURES — Defense Points'),
  heading2('Q: What ethical principles govern this study?'),
  bullet('Declaration of Helsinki (WMA 2013): Human subject research must prioritize patient welfare, voluntary informed consent, and confidentiality.'),
  bullet('Institutional Ethical Review Board (IERB) approval obtained — Annexure I, Ethical Committee approval stamp.'),
  bullet('Informed consent in English (Annexure II) and Urdu (bilingual) — ensures literacy-appropriate consent for Pakistani patients.'),
  heading2('Q: What are the risks to participants?'),
  bullet('Itraconazole: hepatotoxicity (rare at standard doses), drug interactions (CYP3A4), nausea, headache.'),
  bullet('Consent form states "No known risks" — this is an understatement; the committee may question it. Be prepared to acknowledge that itraconazole is a prescription drug with recognized side effects and that liver function will be monitored.'),
  bullet('FESS: standard surgical risks (bleeding, infection, orbital/CSF complications) — covered under standard surgical consent.'),
  heading2('Q: How is confidentiality protected?'),
  bullet('Patient data recorded using serial numbers only on performa — name not linked to analysis data.'),
  bullet('Results reported in aggregate form; no individual identification.'),
  heading2('Annexure III — Cost estimate'),
  bullet('All investigations and procedures are covered by hospital resources — reducing financial burden on patients, appropriate for a public sector study.'),
  bullet('Stationery (PKR 2000) and miscellaneous (PKR 3000) — nominal costs borne by researcher.'),
  heading2('Annexure IV — Plan of Work'),
  bullet('Gantt-style activity schedule across 12 months: patient enrollment → surgery/data collection → analysis → thesis writing → submission. Logical and achievable.'),
  heading2('Annexure V — Data Collection Performa'),
  bullet('Collects: Name, Reg No., Age, Gender, Duration of symptoms, Nose involved (L/R), PMH (DM, HTN, Smoking), Group allocation, Post-op SNOT-20 and Lund-Mackay scores at 6, 12, and 24 weeks.'),
  bullet('Note: 24 weeks = 6 months; the follow-up in the performa goes to 24 weeks, not 12 months — committee may flag the discrepancy with the 12-month follow-up stated in the methodology (see Error Page).'),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// ERROR PAGE (1 of 2)
// ─────────────────────────────────────────────
const errorPage1 = [
  new Paragraph({
    children: [new TextRun({ text: '⚠ ERRORS, INCONSISTENCIES & POINTS REQUIRING CLARIFICATION', bold: true, size: 36, color: 'C0392B' })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 200, after: 200 },
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Page 1 of 2  —  Highlighted for Pre-Defense Review', italics: true, size: 22, color: '666666' })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 0, after: 300 },
  }),

  ...sectionBox('ERROR 1 — Typo in Section Header (Research Methodology Page)', [
    errorBullet('Page 14 (Research Methodology section header) is typed as "RESREACH METHODOLOGY" — a clear typographical error.'),
    warnLabel('Correction', 'Should read: "RESEARCH METHODOLOGY"'),
    warnLabel('Severity', 'Minor — but unprofessional in a formal UHS synopsis submission.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 2 — SNOT-20 vs SNOT-22 Inconsistency', [
    errorBullet('The Project Summary (Page 1) and Data Performa (Annexure V) use "SNOT-20" throughout.'),
    errorBullet('The Literature Review and Research Methodology sections repeatedly reference "SNOT-22" (the validated 22-item version used in all cited published studies).'),
    warnLabel('Problem', 'SNOT-22 is the internationally validated and widely used version (Hopkins 2009); SNOT-20 is an older, less validated form. Using different versions across sections is internally inconsistent.'),
    warnLabel('Correction', 'Standardize to SNOT-22 across all sections, or explicitly justify the use of SNOT-20 with a reference.'),
    warnLabel('Severity', 'Moderate — committee will likely ask about this.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 3 — Itraconazole Dose Not Specified', [
    errorBullet('The synopsis mentions "oral itraconazole for a defined period (typically 2–4 weeks)" in the methodology but never specifies the dose (mg/day).'),
    errorBullet('Operational definitions state "4 weeks pre-op" and "4 weeks post-op" but methodology says "2–4 weeks pre-op" and "4–6 weeks post-op" — contradictory.'),
    warnLabel('Correction', 'Specify exact dose: e.g., Itraconazole 200 mg twice daily (400 mg/day) for 4 weeks pre-op (Group A) or 6 weeks post-op (Group B), as per Salil 2023 and Aggarwal 2023.'),
    warnLabel('Severity', 'Significant — a comparative pharmacological study must define exact drug dose and duration.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 4 — Data Performa Follow-up Duration Mismatch', [
    errorBullet('Annexure V (Data Performa) only records follow-up at 6th week, 12th week, and 24th week (= 6 months max).'),
    errorBullet('The Research Methodology section specifies follow-up at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months.'),
    errorBullet('The Project Summary and recurrence definition explicitly state "12 months post-FESS".'),
    warnLabel('Problem', 'The performa does not capture the 12-month follow-up data point, which is the primary outcome time point.'),
    warnLabel('Correction', 'Add a 48th week (12-month) row to the data performa, and ideally add separate rows for 2-week, 4-week, and 3-month follow-ups as specified in the methodology.'),
    warnLabel('Severity', 'Significant — the primary outcome cannot be captured with the current performa design.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 5 — Inadequate Reference Format (3 References)', [
    errorBullet('"Academic.oup.com, 2015" is cited as a reference — this is a URL/website name, not a valid academic reference.'),
    errorBullet('"Pubmed.ncbi.nlm.nih.gov, 2022" — same problem; a PubMed URL is not a reference.'),
    errorBullet('"Journals.ekb.eg, 2024" — same problem; Egyptian Knowledge Bank URL without author/title/journal.'),
    warnLabel('Correction', 'These should be replaced with full references: Author(s), Year, Title, Journal, Volume, Pages, DOI.'),
    warnLabel('Note', '"Prospective Comparative Study, 2022" with URL https://pubmed.ncbi.nlm.nih.gov/36478077/ — this is Salil A, Joy N, Faizal B. The URL resolves to PMID 36478077. It should be cited as the Salil et al. 2023 reference (which is separately listed).'),
    warnLabel('Severity', 'Moderate — academically unacceptable reference formatting.'),
  ]),
  divider(),
  pageBreak(),
];

// ─────────────────────────────────────────────
// ERROR PAGE (2 of 2)
// ─────────────────────────────────────────────
const errorPage2 = [
  new Paragraph({
    children: [new TextRun({ text: '⚠ ERRORS, INCONSISTENCIES & POINTS REQUIRING CLARIFICATION', bold: true, size: 36, color: 'C0392B' })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 200, after: 200 },
  }),
  new Paragraph({
    children: [new TextRun({ text: 'Page 2 of 2  —  Highlighted for Pre-Defense Review', italics: true, size: 22, color: '666666' })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 0, after: 300 },
  }),

  ...sectionBox('ERROR 6 — Non-Randomized Allocation Stated, Then "Random Number Table" Used', [
    errorBullet('The Study Design states: "Quasi experimental study" implying non-randomized allocation.'),
    errorBullet('The Research Methodology section states: "Patients will be randomly divided into two groups using a random number table."'),
    warnLabel('Problem', 'A study cannot be simultaneously quasi-experimental (non-randomized) AND use random number table allocation. This is a fundamental methodological contradiction.'),
    warnLabel('Clarification needed', 'If random number tables are used, the study is an RCT (or at minimum a randomized controlled trial). If it is quasi-experimental, allocation must be by another defined method (e.g., alternating assignment, pre-defined sequence). Choose one and be consistent throughout.'),
    warnLabel('Severity', 'Major — the committee will almost certainly flag this.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 7 — Recurrence Performa Column Mismatch with Methodology', [
    errorBullet('Annexure V header title says "Allergic Fungal Rhinosinusitis Recurrence" but no column for recurrence (Yes/No) is included in the performa.'),
    errorBullet('The performa only records SNOT-20 and Lund-Mackay scores — it omits the Kupferberg NE grade column entirely, despite Kupferberg staging being stated as an outcome measure throughout the synopsis.'),
    warnLabel('Correction', 'Add a "Kupferberg Grade" column and a "Recurrence (Yes/No)" column to the data collection performa.'),
    warnLabel('Severity', 'Significant — missing outcome columns mean primary and secondary outcome data cannot be recorded.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 8 — "Itraconazole, H. et al., 2024" Reference Format Error', [
    errorBullet('One reference is listed as: "Itraconazole, H. et al., 2024. Prolonged itraconazole therapy..." — "Itraconazole" cannot be a surname.'),
    errorBullet('The correct citation (PMID 37377280) is: Shah B, Kajal S, Bhalla AS. Prolonged Itraconazole Therapy as Sole Treatment for Patients with Allergic Fungal Rhinosinusitis. Laryngoscope. 2024 Feb;134(2):545-551.'),
    warnLabel('Correction', 'Replace with correct author names: Shah B, Kajal S, Bhalla AS, et al., 2024.'),
    warnLabel('Severity', 'Moderate — a committee member who knows the field will immediately recognize this.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 9 — Consent Form: "No Known Risks"', [
    errorBullet('The consent form states: "Possible Risks: There is no known risk to the patients participating in this study."'),
    errorBullet('Itraconazole is an azole antifungal with known hepatotoxicity, drug interactions, teratogenicity, and QTc prolongation risk (when combined with certain drugs).'),
    warnLabel('Correction', 'Consent form should state: "Itraconazole may cause mild side effects including nausea, headache, skin rash, and rarely liver enzyme elevation. Liver function tests will be monitored. Please inform the researcher of all medications you are taking."'),
    warnLabel('Severity', 'Moderate — an ethics committee or professor will flag this as a safety concern.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('ERROR 10 — Objective is Singular; Study Measures Multiple Outcomes', [
    errorBullet('The synopsis has only ONE objective, which is a compound statement combining primary and secondary outcomes.'),
    warnLabel('Suggestion', 'Separate into one primary and 2–3 secondary objectives for clarity, as expected in a UHS MS synopsis format.'),
    warnLabel('Example Primary', 'To compare recurrence rates at 12 months post-FESS between pre-operative and post-operative itraconazole groups.'),
    warnLabel('Example Secondary 1', 'To compare SNOT-22 scores between the two groups at 3, 6, and 12 months post-FESS.'),
    warnLabel('Example Secondary 2', 'To compare endoscopic (Kupferberg) and radiologic (Lund-Mackay) outcomes between the two groups.'),
    warnLabel('Severity', 'Minor — presentation issue; does not invalidate the study but is suboptimal.'),
  ]),
  new Paragraph({ spacing: { before: 100 } }),

  ...sectionBox('SUMMARY TABLE OF ERRORS', [
    new Paragraph({ spacing: { before: 60 } }),
  ]),
];

// ─────────────────────────────────────────────
// Error Summary Table
// ─────────────────────────────────────────────
function makeErrorTable() {
  const headers = ['#', 'Error', 'Severity', 'Correction'];
  const rows_data = [
    ['1', 'Typo: "RESREACH METHODOLOGY"', 'Minor', 'Fix spelling'],
    ['2', 'SNOT-20 vs SNOT-22 inconsistency', 'Moderate', 'Standardize to SNOT-22'],
    ['3', 'Itraconazole dose not specified', 'Significant', 'State exact dose (e.g. 200mg BD × 4–6 weeks)'],
    ['4', 'Data performa stops at 24 weeks; study needs 12-month data', 'Significant', 'Add 48-week follow-up row'],
    ['5', 'Three URL-only references (no author/journal)', 'Moderate', 'Replace with full citation format'],
    ['6', 'Quasi-experimental label contradicts "random number table" allocation', 'Major', 'Clarify design; choose RCT or quasi-experimental'],
    ['7', 'Kupferberg grade and Recurrence columns missing from performa', 'Significant', 'Add columns to data performa'],
    ['8', '"Itraconazole, H. et al." incorrect surname', 'Moderate', 'Correct to Shah B, Kajal S, Bhalla AS 2024'],
    ['9', 'Consent form states "no known risks" for itraconazole', 'Moderate', 'Add side effects to consent form'],
    ['10', 'Single compound objective; should be split', 'Minor', 'Separate into primary + secondary objectives'],
  ];
  const tableRows = [
    new TableRow({
      children: headers.map(h =>
        new TableCell({
          children: [new Paragraph({ children: [new TextRun({ text: h, bold: true, size: 20, color: 'FFFFFF' })], alignment: AlignmentType.CENTER })],
          shading: { type: ShadingType.CLEAR, color: '1A5276' },
          verticalAlign: VerticalAlign.CENTER,
        })
      ),
    }),
    ...rows_data.map((row, idx) =>
      new TableRow({
        children: row.map((cell, ci) =>
          new TableCell({
            children: [new Paragraph({
              children: [new TextRun({
                text: cell,
                size: 19,
                color: ci === 2 ? (cell === 'Major' ? 'C0392B' : cell === 'Significant' ? 'E67E22' : cell === 'Moderate' ? '2980B9' : '27AE60') : '000000',
                bold: ci === 2,
              })],
              alignment: ci === 0 ? AlignmentType.CENTER : AlignmentType.LEFT,
            })],
            shading: { type: ShadingType.CLEAR, color: idx % 2 === 0 ? 'FDFEFE' : 'EBF5FB' },
          })
        ),
      })
    ),
  ];
  return new Table({
    rows: tableRows,
    width: { size: 100, type: WidthType.PERCENTAGE },
    columnWidths: [400, 2500, 1200, 4000],
  });
}

// ─────────────────────────────────────────────
// ASSEMBLE DOCUMENT
// ─────────────────────────────────────────────
const doc = new Document({
  styles: {
    default: {
      document: {
        run: { font: 'Calibri', size: 22 },
        paragraph: { spacing: { line: 360 } },
      },
    },
    paragraphStyles: [
      {
        id: 'Heading1',
        name: 'Heading 1',
        run: { bold: true, size: 32, color: '1A5276', font: 'Calibri' },
        paragraph: { spacing: { before: 300, after: 120 } },
      },
      {
        id: 'Heading2',
        name: 'Heading 2',
        run: { bold: true, size: 24, color: '21618C', font: 'Calibri' },
        paragraph: { spacing: { before: 200, after: 80 } },
      },
      {
        id: 'Heading3',
        name: 'Heading 3',
        run: { bold: true, size: 22, color: '2874A6', font: 'Calibri' },
        paragraph: { spacing: { before: 140, after: 60 } },
      },
    ],
  },
  sections: [
    {
      properties: {
        page: {
          margin: { top: 1200, right: 1200, bottom: 1200, left: 1200 },
        },
      },
      headers: {
        default: new Header({
          children: [
            new Paragraph({
              children: [
                new TextRun({ text: 'Synopsis Defense — Dr. Danish Rehman | MS ENT | AFRS/FESS/Itraconazole', size: 18, color: '666666', italics: true }),
              ],
              alignment: AlignmentType.RIGHT,
            }),
          ],
        }),
      },
      footers: {
        default: new Footer({
          children: [
            new Paragraph({
              children: [
                new TextRun({ text: 'Page ', size: 18, color: '666666' }),
                new PageNumber({ type: NumberFormat.DECIMAL }),
                new TextRun({ text: ' | Sahiwal Teaching Hospital, UHS Lahore', size: 18, color: '666666' }),
              ],
              alignment: AlignmentType.CENTER,
            }),
          ],
        }),
      },
      children: [
        ...coverPage,
        ...page1,
        ...page2,
        ...page3,
        ...page4,
        ...page5,
        ...page6,
        ...page7,
        ...page8,
        ...page9,
        ...page10,
        ...page11,
        ...page12,
        ...page13,
        ...page14,
        ...page15,
        ...page16,
        ...errorPage1,
        ...errorPage2,
        makeErrorTable(),
        new Paragraph({ spacing: { before: 400 } }),
        new Paragraph({
          children: [new TextRun({ text: 'End of Defense Document', bold: true, size: 22, color: '1A5276', italics: true })],
          alignment: AlignmentType.CENTER,
        }),
      ],
    },
  ],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/danish-defense/Danish_Synopsis_Defense.docx', buffer);
  console.log('Done: Danish_Synopsis_Defense.docx');
});

cd /home/daytona/workspace/danish-defense && node create_defense.js 2>&1

~/danish-defense/create_defense.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/danish-defense/create_defense.js'

cd /home/daytona/workspace/danish-defense && node create_defense.js 2>&1

~/danish-defense/create_defense.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/danish-defense/create_defense.js'

cd /home/daytona/workspace/danish-defense && node create_defense.js 2>&1

~/danish-defense/create_defense.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/danish-defense/create_defense.js'

~/danish-defense/create_defense.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/danish-defense/create_defense.js'

cd /home/daytona/workspace/danish-defense && node create_defense.js 2>&1 && echo…